Search Results
Your search for s matches 7010 pages
Showing 6151 - 6200Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study
Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...
FDA Approves New Indication for Ibrutinib in Waldenström's Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Age-Related Clonal Hematopoiesis Associated With Increased Risk of All-Cause Mortality, Heart Disease, and Stroke, as Well as Blood Cancer
In a study reported in The New England Journal of Medicine, Jaiswal et al found somatic mutations associated with hematologic cancers at increasing frequency with increasing age, with presence of the mutations being associated with increased risk of hematologic cancers, all-cause mortality,...
Study Finds Many Women Lack Understanding of Their Breast Cancer, Especially Minority Patients
A population-based study of women who had undergone surgery for breast cancer has found that many lacked understanding of the basic characteristics of their disease, including stage, grade, and tumor characteristics. Minority patients were less likely than white patients to have the correct...
Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
New Breast Exam Nearly Quadruples Detection of Invasive Breast Cancers When Added to Screening Mammography in Women With Dense Breast Tissue
A new breast imaging technique developed at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a study published by Rhodes et al in the American Journal of Roentgenology. What Is MBI? Molecular breast imaging...
Head and Neck Cancers in Young Adults More Likely to Be a Result of Inherited Factors
Data from 25 case-control studies and separate analyses show that head and neck cancers in young adults are more likely to occur as a result of inherited factors rather than lifestyle factors, such as smoking or drinking alcohol, according to a new study by Toporcov et al published in the...
Genetic Diagnosis by Exome Sequencing Feasible for Familial Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Chubb et al found that genetic diagnosis of high-penetrance susceptibility to colorectal cancer can be achieved in a sizeable proportion of familial colorectal cancer cases via exome sequencing for germline mutations. Study Details The...
Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
Poor Health Status More Common Among Childhood Cancer Survivors vs Siblings, With Age‑Related Increase in Prevalence
In a study in the Childhood Cancer Survivor Cohort reported in the Journal of Clinical Oncology, Hudson et al found that poor health status was more common in survivors than in siblings, with an age-related increase in prevalence particularly evident in female survivors. In the study, 22,568...
Next-Generation Sequencing Uncovers Potential Genetic Drivers of Rare Breast Tumors
A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of phyllodes tumors, a rare type of breast tumor. The study offers the first comprehensive analysis of the molecular alterations at work in these tumors, according to Cani...
ASCO Announces Progress in the Development of CancerLinQ, With the First Version Due in Late 2015
The American Society of Clinical Oncology (ASCO) announced today that it will use SAP HANA®, a data management and application platform, in the development of CancerLinQ, the Society’s health information technology platform that will harness Big Data to deliver high-quality care to...
ASCO Releases Annual Report on Progress Against Cancer and Names the Cancer Advance of the Year
ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, today, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). ASCO credits the improvements in CLL care with the...
Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC
In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...
Low Sentinel Node Biopsy False-Negative Rate With Immunohistochemistry After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer
In the phase II SN FNAC (Sentinel Node Biopsy Following Neoadjuvant Chemotherapy) trial, reported in the Journal of Clinical Oncology, Boileau et al found a sentinel node biopsy false-negative rate of 8.4% with mandatory use of immunohistochemistry and a sentinel node biopsy identification rate of...
Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost
A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...
Are Physicians Choosing Wisely When Imaging for Distant Metastases in Early-Stage Breast Cancer?
Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines, and a recommendation from ASCO to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients...
Study Finds Decreasing Rates of Primary Tumor Resection and Better Survival Among Patients With Advanced Colorectal Cancer
The annual rate of primary tumor removal for stage IV colorectal cancer has decreased since 1988, and the trend toward nonsurgical management of the disease noted in 2001 coincides with the availability of newer chemotherapy and biologic treatments, according to study reported by Hu et al in JAMA...
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Frazier et al used data from U.S. and UK clinical trials to identify a high-risk group of patients with pediatric extracranial germ cell tumors. Study Details The study involved data from seven germ cell tumor trials conducted by the...
Combining Newer, More Intensive First-Line Chemotherapy With Bevacizumab Improves Long-Term Outcome in Advanced Colorectal Cancer
Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan) chemotherapy in combination with bevacizumab (Avastin) is superior to the standard FOLFIRI (leucovorin, 5-FU,...
Second-Line Ramucirumab Added to Standard Chemotherapy Improves Survival in Patients With Advanced Colorectal Cancer
New findings from an international phase III study of 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy indicate that a combination of the targeted drug ramucirumab (Cyramza) and FOLFIRI (irinotecan, fluorouracil, leucovorin) chemotherapy provides a ...
Chemoradiation Plus Nonsurgical Management of Rectal Cancer Appears Safe, May Offer Better Quality of Life Than Surgery
A retrospective review of clinical data on 145 patients with stage I to III rectal cancer indicates that patients who achieved complete response after treatment with chemoradiation and systemic chemotherapy had similar 4-year survival rates regardless of whether they had immediate surgery or...
Higher Vitamin D Levels Associated With Markedly Improved Survival in Patients With Advanced Colorectal Cancer
A prospective analysis of data from a phase III study of patients newly diagnosed with metastatic colorectal cancer indicates that patients with higher vitamin D levels have better outcomes after treatment with chemotherapy and targeted therapy. The median overall survival for patients with the...
Long-Term Follow-up Shows Favorable Overall Survival Rates With Concurrent Neoadjuvant Chemoradiotherapy Regimens in Rectal Cancer
Patients with locally advanced rectal cancer who receive neoadjuvant radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a 4-year overall survival rate of 85% and 75%, respectively, according to a study reported by Wong et al in the International Journal ...
New Cancer Diagnoses Associated With Increased Risk of Stroke
Patients with new cases of cancer face a heightened risk of stroke in the months immediately following their diagnoses, with that risk escalating with the aggressiveness of their disease, according to a new study from researchers at Weill Cornell Medical College and Memorial Sloan Kettering Cancer...
Chemotherapy Plus Targeted Therapy Reduces Recurrence in Women With Early-Stage HER2-Positive Breast Cancer
A phase II clinical study of adjuvant paclitaxel and trastuzumab (Herceptin) in women with stage I HER2-positive breast cancer has found the 3-year rate of survival free from invasive disease was 98.7%. The findings may help establish the combination therapy as the first standard treatment approach ...
Study Finds Whole-Genome Sequencing Is Successful in Identifying Patients’ Risk for Inherited Cancers
After performing whole-genome sequencing on patients found to have BRCA1or BRCA2 mutations as well as on those that were not carriers of either mutation, researchers found cancer risk–related potentially pathogenic variants in those without BRCA mutations. While the results highlight the ...
FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Soligenix’s synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation is reserved for drugs that demonstrate the potential to address an...
Bispecific CD19-Directed CD3 T-Cell Engager Blinatumomab Active in Adults With Relapsed/Refractory B-Cell Precursor ALL
In a phase II study reported in The Lancet Oncology, Topp et al found that the bispecific CD19-directed CD3 T-cell engager (BiTE) blinatumomab (Blincyto) was highly active in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab binds to CD19 expressed ...
Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer
Adding radiation treatment to androgen-deprivation therapy saves more lives among older men with locally advanced prostate therapy than androgen-deprivation therapy alone, according to a new study reported by Bekelman et al in the Journal of Clinical Oncology. The researchers found that...
More Than 1.5 Million Cancer Deaths Averted During 2 Decades of Dropping Mortality
The American Cancer Society’s annual cancer statistics report found that a 22% drop in cancer mortality over 2 decades led to the avoidance of more than 1.5 million cancer deaths that would have occurred if peak rates had persisted. And while cancer death rates have declined in every state,...
FDA Approves Nivolumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab...
Worse Anxiety/Depression Symptoms in Patients Adopting ‘Helper’ Role in Breast Cancer Internet Support Group
In a study reported in the Journal of Clinical Oncology, Lepore et al found that patients assigned a helper role in a breast cancer Internet support group had worse anxiety/depression symptoms after completion of the intervention than those not assigned a helper role. Study Details In the study,...
Bisphosphonates May Help Prevent Endometrial Cancer
A new analysis suggests that women who use bisphosphonates have about half the risk of developing endometrial cancer as women who do not use the drugs. The findings by Alford et al, published early online in Cancer, supports other research that has shown an anticancer effect of this type of...
No Survival Difference for Adjuvant Capecitabine vs 5-FU With or Without Oxaliplatin in Stage III Colon Cancer
In an analysis reported in The Lancet Oncology, Schmoll et al found no difference in survival outcomes with adjuvant capecitabine vs fluorouracil (5-FU)/leucovorin with or without oxaliplatin in patients with stage III colon cancer and no adverse impact of adjuvant oxaliplatin on post-relapse...
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer
Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three ...
PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the PD-1 pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of PD-L1 and PD-L2 and promoting...
Long Noncoding RNAs Are a Novel Prognostic Marker in Older Patients With Acute Leukemia
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) describes a novel marker that might help doctors choose the least toxic, most effective treatment for many...
Higher Levels of Physical Activity Improve Survival Among Men With Prostate Cancer
Men with localized prostate cancer who walked or cycled for 20 minutes or more a day had a 30% decreased overall mortality and a 39% decreased prostate cancer–specific mortality compared with men who spent less time engaging in those activities, a large Swedish study has found. The study...
Racial Disparities in Colon Cancer Survival Linked to Advanced Disease and Comorbidities at Diagnosis
Racial disparities in colon cancer survival rates may be explained by differences in the health of the patients at diagnosis—both in the stage of the cancer and comorbid conditions—rather than by differences in subsequent treatment, a new study has found. Focusing efforts on prevention...
Germline SUFU Mutations Cause Gorlin Syndrome and Increase Risk for Childhood Medulloblastoma
In a study to identify causative mutations in patients with Gorlin syndrome without PTCH1 mutations, Smith et al found that germline mutations in SUFU were associated with Gorlin syndrome and with increased likelihood of Gorlin syndrome–associated childhood medulloblastoma. The study is...
SABCS 2014: BOLERO-3: Everolimus Plus Trastuzumab/Paclitaxel Misses the Mark in First-Line HER2 Advanced Breast Cancer
The addition of everolimus to weekly trastuzumab (Herceptin) plus paclitaxel did not improve outcomes in the phase III BOLERO-1/TRIO-019, but did provide a “signal” in the hormone receptor–negative subset. The study was reported at the 2014 San Antonio Breast Cancer Symposium by...
SABCS 2014: Fulvestrant Improves Survival Over Anastrozole for Patients With Advanced Breast Cancer
Among patients with advanced, hormone receptor–positive breast cancer who had not been treated previously for advanced disease, those who took fulvestrant (Faslodex) lived longer than those who took anastrozole, according to data from the phase II FIRST trial presented at the 2014 San Antonio ...
SABCS 2014: Lowering Dietary Fat Intake Reduces Death Rates in Some Women With Breast Cancer
Among early-stage breast cancer patients who reduced their dietary fat intake for 5 years following a diagnosis, after over 15 years follow-up, death rates from all causes were significantly reduced in those who had hormone-unrelated breast cancer, according to data from the Women’s...
SABCS 2014: Adding Carboplatin to Neoadjuvant Therapy Increases Pathologic Complete Response Rates Across Subtypes in Triple-Negative Breast Cancer
Among women with triple-negative breast cancer, both basal-like and non–basal-like tumors were equally likely to demonstrate a pathologic complete response to neoadjuvant chemotherapy, but they responded differently to exposure to carboplatin and bevacizumab (Avastin), in an analysis of the...
FDA Approves Nine-Valent HPV Vaccine for Prevention of Certain Cancers Caused by Five Additional Types of HPV
The U.S. Food and Drug Administration (FDA) today approved recombinant nine-valent human papillomavirus vaccine (Gardasil 9) for the prevention of certain diseases caused by nine types of HPV. The nine-valent vaccine covers five more HPV types than the previously approved quadrivalent vaccine...
SABCS 2014: Pembrolizumab Holds Promise in Breast Cancer, Early Studies Suggest
Single-agent treatment with the immunotherapy drug pembrolizumab (Keytruda) produced a “signal of activity” and led to some durable response, in patients with metastatic triple-negative breast cancer, Rita Nanda, MD, of the University of Chicago, reported at the 2014 San Antonio Breast...
